Duodenal Mucosal Ablation Promising for Blood Sugar Control in Type 2 Diabetes: Study Finds

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-30 03:45 GMT | Update On 2025-08-30 06:58 GMT

UK: A new meta-analysis published in BMJ Frontline Gastroenterology highlights the potential of duodenal mucosal ablation (DMA) as a novel endoscopic approach for improving blood sugar control in people with inadequately managed type 2 diabetes mellitus (T2DM).

The research, led by Benjamin Charles Norton and colleagues from University College London, systematically assessed the efficacy and safety of DMA across currently available technologies, providing important insights into its clinical role.

DMA is designed to selectively target and ablate the thickened duodenal lining, which is thought to play a role in impaired glucose metabolism. By reshaping the mucosa, the therapy aims to restore better metabolic control, particularly in patients whose diabetes remains uncontrolled despite standard treatment.

The team conducted a comprehensive search of Medline, Cochrane, and Scopus databases to identify studies reporting outcomes on DMA up to June 2024. Eight studies, comprising 341 patients, were included in the pooled analysis. These investigations covered both thermal ablation techniques (such as REVITA and RFVA) and non-thermal modalities (such as ReCET).

The study revealed the following notable findings:

HbA1c levels dropped by an average of 1.13% at six months following duodenal mucosal ablation (DMA).
This improvement was consistent across different technologies, though variability between studies was observed.
Factors such as patient lifestyle and treatment adherence may have contributed to the observed heterogeneity.
Serious adverse events (SAEs) were infrequent, ranging between 0% and 14.3% in individual studies.
The pooled estimate showed a low overall SAE rate of just 2%, highlighting the favourable safety profile of DMA.

The authors emphasised that while DMA shows encouraging results, its full potential could be realised by refining procedural aspects, such as extending the ablation length, alongside optimising patient-level factors. This dual approach could help reduce variability in outcomes and maximise therapeutic benefit.

“DMA appears to offer a reliable reduction in HbA1c for patients struggling with glycaemic control, and importantly, it does so with a relatively low risk of serious complications,” the researchers wrote.

The findings support DMA as an emerging adjunctive therapy for type 2 diabetes, particularly for individuals who do not achieve sufficient control with conventional measures. However, the study also calls for further long-term research to clarify the durability of response, refine procedural techniques, and better understand how patient characteristics influence outcomes.

"The analysis provides compelling evidence that duodenal mucosal ablation can deliver meaningful improvements in blood glucose management with an acceptable safety profile, positioning it as a promising tool in the expanding therapeutic landscape for type 2 diabetes," the authors concluded.

Reference:

Norton BC, Papaefthymiou A, Telese A, et alPerformance and safety of duodenal mucosal ablation in the management of type 2 diabetes: a systematic review and meta-analysisFrontline Gastroenterology Published Online First: 24 August 2025. doi: 10.1136/flgastro-2025-103211

Article Source : Frontline Gastroenterology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Duodenal Mucosal Ablation Promising for Blood Sugar Control in Type 2 Diabetes: Study Finds

Similar News

Cachexia index as a Biomarker for Cancer Cachexia and Quality of Life in Gastric Cancer: Study

First global guidelines for pregnancy and inflammatory bowel disease developed

Death from Liver Disease in Parents Linked to Elevated Hepatitis Risk in Children: Study Finds

Even Heavy Drinkers Benefit: How Healthy Eating and Exercise Protect the Liver, Study Provides Insights

Study reveals beneficial effects of diet and exercise on alcohol-related adverse liver health

Endoscopy Every Three Years Cuts Gastric Cancer Death Risk: Cohort Study

New Study Discovers Fat-Trapping Green Tea Beads for Safe Weight Loss